Investigation Report on China Megestrol Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||331523|
|出版日期||內容資訊||英文 30 Pages
|中國的Megestrol市場分析:2010年∼2019年 Investigation Report on China Megestrol Market, 2010-2019|
|出版日期: 2015年05月28日||內容資訊: 英文 30 Pages||
Nowadays, breast cancer has the highest incidence among malignancy for women all over the world. According to the statistics released by World Health Organization (WHO), the number of breast cancer cases around the world reaches 1.2 million per year while a global death toll is about 0.5 million per year. In the past decade, the annual growth rate of the incidence of breast cancer hit 8%. By 2020, the incidence of cancer will increase by 50% and the number of new cases of cancer around the world will reach 15 million per year.
In recent years, the growth rate of the incidence of breast cancer in China ranks first in the world with one in ten women suffering from breast cancer. In 2015, the number of new cases of breast cancer in China has surpassed that of the US and become the largest in the world. In 2014, the number of newly confirmed cases of breast cancer was 0.225 million, increasing sharply by 50% compared with 2004. At the same time, nearly two thirds of newly confirmed cases can survive for more than 20 years with a long-term survival rate rising sharply by 20%. According to WTO, this astonishing progress benefits from the discovery and sale of new drugs with better efficacy and fewer adverse reactions.
About two thirds of breast cancer patients use hormone therapy. Common varieties of progestin are medroxyprogesterone and megestrol which act by blocking the source of human estrogen with an unsatisfactory efficacy rate of 30%-50%. Since their efficacy is not better than other drugs for breast cancer and their price is relatively high, their sales is not very big. But according to the latest domestic reports, progestin occupies nearly 2% of clinical medication for breast cancer with rising sales. After entering Chinese market, Megestrol develops very fast. Although its sales in 2011 underwent a small decline, it still enjoys an obvious growth trend in recent years. The annual sales of megestrol rose from CNY 29.95 million in 2010 to CNY 37.22 million in 2014 with a compound growth rate of 5.58%.
Readers can get at least the following information through this report:
The author suggests the following groups of people purchase this report: